Cannabis-derived drug shows promise for cognitive decline
Therapix Biosciences demonstrates reversal of age-related cognitive impairment in pre-clinical study
New pre-clinical data shows that a low dose of a proprietary tetrahydrocannabinol (THC) drug candidate developed by Israel’s Therapix Biosciences significantly reversed age-related cognitive impairment in old mice.
Therapix focuses on the development of cannabinoid-based drugs. The candidate dubbed THX-ULD01 is intended for the treatment of mild cognitive impairment (MCI).
Tags
Who is online
99 visitors
MCI is an intermediate stage between the expected cognitive decline of normal aging and the more serious decline of dementia. It can involve problems with memory, language, thinking and judgment that are greater than normal age-related changes but are not severe enough to interfere with daily life or independent function.
“The model demonstrated a relatively long-lasting increase in neuroprotection and neuroplasticity, as well as a larger volume and higher tissue density in various regions of the brain of THC-treated old mice as measured by MRI,” said Sarne.